Director/PDMR Shareholding

Arix Bioscience Plc

02 May 2023

 

Arix Bioscience plc
("Company")

PDMR notifications & Director Shareholdings

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Arix Bioscience Plc has been notified of the following transactions relating to the below named PDMRs and their respective interests in the ordinary share capital of the Company ('Shares'):

Peregrine Moncreiffe, Non-Executive Director and Chairman of the Board purchased 75,000 Ordinary shares of 0.001 pence each in the Company ("Shares") on 27 April 2023 at a price of 102.5 pence per share and purchased a further 85,000 Shares in the Company on 28 April 2023 at a price of 104.8 pence per share.  

Debra Barker, Non-Executive Director and Senior Independent Director purchased 24,000 Shares in the Company on 27 April 2023 at a price of 103 pence per share.

Robert Lyne, Chief Executive Officer purchased 24,330 Shares in the Company on 27 April 2023 at a price of 102.75 pence per share.

In a separate transaction, Robert Lyne exercised vested options over 203,764 shares ("Option Shares") on 27 April 2023 pursuant to a nil cost share award granted on 30 June 2020. 96,107 of the Shares were sold on 27 April 2023 at a sale price of 101.5 pence per share to satisfy the resultant income tax and National Insurance liability.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further detail on the respective transactions.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Peregrine Moncreiffe
2	Reason for the notification
a)	Position/status	Non-Executive Director and Chair of the Board
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Arix Bioscience plc Ordinary shares of 0.001 pence each
	Identification code	GB00BD045071
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)		Price(s)£	Volume(s)
	27 April           2023 28 April          2023		1.025 1.048	75,000      85,000
d)	Aggregated information
	- Aggregated volume	160,000
	- Price	£165,962.50
e)	Date of the transaction	27 April 2023                                                                                                        28 April 2023
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robert Lyne
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Arix Bioscience plc Ordinary shares of 0.001 pence each
	Identification code	GB00BD045071
b)	Nature of the transaction	Share Purchase
c)	Price(s) and volume(s)		Price(s)£	Volume(s)
			£1.0275	24,330
d)	Aggregated information
	- Aggregated volume	N/A (Single Transaction)
	- Price	£24,999.08
e)	Date of the transaction	27 April 2023
f)	Place of the transaction	London Stock Exchange

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robert Lyne
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Arix Bioscience plc Ordinary shares of 0.001 pence each
	Identification code	GB00BD045071
b)	Nature of the transaction	Vesting of awards under the Company's Executive Incentive Plan ("EIP") 2020 and sale of shares to cover associated tax liabilities
c)	Price(s) and volume(s)		Price(s)£	Volume(s)
			1.)      Acquisition £nil per share 2.)       Disposal £1.015	203,764 96,107
d)	Aggregated information
	- Aggregated volume	N/A (Single Transaction)
	- Price	£97,548.61
e)	Date of the transaction	27 April 2023
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Debra Barker
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Arix Bioscience plc Ordinary shares of 0.001 pence each
	Identification code	GB00BD045071
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)		Price(s) £ £1.03.00	Volume(s) 24,000
d)	Aggregated information
	- Aggregated volume	N/A (single transaction)
	- Price	£24,720.00
e)	Date of the transaction	27 April 2023
f)	Place of the transaction	London Stock Exchange

Ends.

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
[phone]

 

END